PE20000425A1 - Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida - Google Patents

Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida

Info

Publication number
PE20000425A1
PE20000425A1 PE1999000301A PE00030199A PE20000425A1 PE 20000425 A1 PE20000425 A1 PE 20000425A1 PE 1999000301 A PE1999000301 A PE 1999000301A PE 00030199 A PE00030199 A PE 00030199A PE 20000425 A1 PE20000425 A1 PE 20000425A1
Authority
PE
Peru
Prior art keywords
heterocycloalkyl
cycloalkyl
aryl
alkyl
heteroalkyl
Prior art date
Application number
PE1999000301A
Other languages
English (en)
Inventor
Biswanath De
Yetunde Olabisi Taiwo
Michael George Natchus
Stanislaw Pikul
Menyan Cheng
Neil Gregory Almstead
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20000425A1 publication Critical patent/PE20000425A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES OH, ALCOXI, NR3OR3; R3 ES H, ALQUILO, ACILO; X ES SO2, CO, CO2, CONR5, POR5, ENLACE; R5 ES H, ALQUILO, HETEROALQUILO, ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILOXI, HETEROARILOXI; R2 ES H, ALQUILO, HETEROALQUILO, ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO, ARILOXI, HETEROARILOXI; Z ES 1)N-W; n ES 1; W ES ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO; 2)N-OR4, N-NR4, N-SR4R4, N-CR4R4R4; n ES 1; R4 ES H, ALQUILO, HETEROALQUILO, ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO; 3)CR6R6; R6 ES H, HALO, ALQUILO, HETEROALQUILO, ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO, CIANO; 4)CICLOALQUILO, HETEROCICLOALQUILO; 5)C=CR4R4; 6)C=V; V ES CICLOALQUILO, HETEROCICLOALQUILO; m Y n SON 0-4; m + n = 2-7. EL COMPUESTO I ES UN INHIBIDOR DE METALOPROTEASAS Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ARTRITIS (OSTEOARTRITIS, ARTRITIS REUMATOIDEA), CANCER (EVITA O CONTRARRESTA EL CRECIMIENTO DE UN TUMOR Y LA METASTASIS), PROBLEMAS CARDIOVASCULARES (CARDIOMIOPATIA DILATADA, INSUFICIENCIA CARDIACA CONGESTIVA, ARTERIOSCLEROSIS, RUPTURA DE PLACA), PROBLEMAS DE LA PIEL, PROBLEMAS OCULARES (ULCERACION DE LA CORNEA, FALTA DE CICATRIZACION DE LA CORNEA, DEGENERACION MACULAR), ENFERMEDADES O INFLAMACION DE LAS ENCIAS (ENFERMEDAD PERIODONTAL, GINGIVITIS)
PE1999000301A 1998-04-14 1999-04-14 Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida PE20000425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8166798P 1998-04-14 1998-04-14

Publications (1)

Publication Number Publication Date
PE20000425A1 true PE20000425A1 (es) 2000-07-13

Family

ID=22165611

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000301A PE20000425A1 (es) 1998-04-14 1999-04-14 Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida

Country Status (21)

Country Link
US (1) US6329418B1 (es)
EP (1) EP1073635A1 (es)
JP (1) JP2002511448A (es)
KR (1) KR100400507B1 (es)
CN (1) CN1297436A (es)
AR (1) AR029145A1 (es)
AU (1) AU753048B2 (es)
BR (1) BR9909620A (es)
CA (1) CA2328211A1 (es)
CO (1) CO5011039A1 (es)
HU (1) HUP0102195A3 (es)
ID (1) ID26925A (es)
IL (1) IL138738A0 (es)
NO (1) NO20005196L (es)
NZ (1) NZ507076A (es)
PE (1) PE20000425A1 (es)
PL (1) PL343529A1 (es)
SK (1) SK15462000A3 (es)
TR (1) TR200002971T2 (es)
WO (1) WO1999052868A1 (es)
ZA (1) ZA200005047B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
EP1268418B1 (en) 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
EA006424B1 (ru) 2000-03-27 2005-12-29 Апплайд Резеч Системз Арс Холдинг Н.В. Фармацевтически активные производные пирролидина
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
MXPA03000504A (es) * 2000-07-19 2003-06-24 Hoffmann La Roche Derivados de pirimidina.
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AU2002256685B2 (en) * 2001-03-20 2008-01-24 Merck Serono Sa Pyrrolidine ester derivatives with oxytocin modulating acitvity
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
ES2296137T3 (es) * 2004-02-26 2008-04-16 Laboratoires Serono Sa Metodo para preparar pirrolidin-oximas.
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
WO2006038265A1 (ja) * 2004-09-30 2006-04-13 Yutaka Imauchi 耳硬化症治療のための医薬組成物
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
TW201113269A (en) 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
CA2953722C (en) 2014-07-02 2022-09-13 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3380992A (en) * 1965-06-14 1968-04-30 Upjohn Co Lincomycin derivatives and process for preparing same
US4377701A (en) * 1981-09-21 1983-03-22 E. R. Squibb & Sons, Inc. 4-Methylene-1-[[(alranoyl or arylcarbonyl)mercapto]acyl]proline and pipecolic acid
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
AU2228292A (en) 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
AU3475393A (en) 1992-01-15 1993-08-03 Merck & Co., Inc. Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
EP1002556A3 (en) 1992-05-01 2001-01-10 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69415159T2 (de) 1993-08-02 1999-07-22 Celltech Therapeutics Ltd Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
GB9316162D0 (en) * 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
KR100418808B1 (ko) 1994-01-20 2004-07-23 브리티쉬 바이오테크 파마슈티칼스 리미티드 금속단백질분해효소억제제
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
DE69529100T2 (de) 1994-01-22 2003-07-17 British Biotech Pharm Metalloproteinaseinhibitoren
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9404046D0 (en) 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
AU2394795A (en) 1994-04-28 1995-11-29 Du Pont Merck Pharmaceutical Company, The Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9412350D0 (en) 1994-06-20 1994-08-10 Fujisawa Pharmaceutical Co New compound and its preparation
NZ288299A (en) 1994-06-22 1998-06-26 British Biotech Pharm Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
TR199800990T2 (xx) 1995-12-08 1998-07-21 Agouron Pharmaceuticals, Inc. Metaloproteinaz inhibit�rleri, bunlar� i�eren farmas�tik bile�imler, bunlar�n farmas�tik kullan�mlar� ve bunlar�n �retiminde kullan�labilecek y�ntemler ve ara �r�nler.
IL128666A (en) 1996-08-28 2005-09-25 Procter & Gamble Substituted cyclic amine metalloprotease inhibitors

Also Published As

Publication number Publication date
PL343529A1 (en) 2001-08-27
NO20005196L (no) 2000-12-14
AR029145A1 (es) 2003-06-18
TR200002971T2 (tr) 2001-02-21
CO5011039A1 (es) 2001-02-28
ID26925A (id) 2001-02-22
HUP0102195A3 (en) 2001-12-28
AU3552299A (en) 1999-11-01
US6329418B1 (en) 2001-12-11
SK15462000A3 (sk) 2001-06-11
JP2002511448A (ja) 2002-04-16
IL138738A0 (en) 2001-10-31
KR100400507B1 (ko) 2003-10-08
EP1073635A1 (en) 2001-02-07
WO1999052868A1 (en) 1999-10-21
NO20005196D0 (no) 2000-10-16
CN1297436A (zh) 2001-05-30
BR9909620A (pt) 2000-12-19
ZA200005047B (en) 2001-06-06
HUP0102195A2 (hu) 2001-11-28
NZ507076A (en) 2003-04-29
CA2328211A1 (en) 1999-10-21
AU753048B2 (en) 2002-10-03
KR20010042694A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
PE20000425A1 (es) Inhibidores de metaloproteasa de hidroxamato pirrolidina sustituida
MX9804793A (es) Acidos arilsulfonamido-hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral-alfa y de metaloproteinasa de matriz.
DE69810134T2 (de) Amide derivativen zur behandlung von durch cytokinen vermittelten krankheiten
BR9408246A (pt) Composto derivado de 3-azabicicloalcano N-substituído
NO20012975L (no) Nye bifenyl og bifenylanaloge forbindelser som integrinantagonister
BR1100131A (pt) ácidos hidroxâmicos substituìdos por arilsulfonamido
DE69921804D1 (de) Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten
MY117896A (en) Quinazoline derivatives
PT672041E (pt) Derivados da piridina farmacologicamente activos e processos para a sua preparacao
HUP9802762A2 (hu) Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DE69724140D1 (de) Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente
DE69723258T2 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
PT649846E (pt) Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
DE69418744T2 (de) Verwendung von Pregnanderivaten zur Behandlung von Tumoren
ATE407710T1 (de) Implantat für den transport und die freigabe von pharmakologisch aktiven substanzen
AR003416A1 (es) Nuevos derivados de acido hidroximico, procedimiento para preparar dichos derivados, compuestos intermediarios de aplicacion exclusiva en dichoprocedimiento, composiciones plaguicidas y procedimientos para el tratamiento de plantas con dichos derivados.
ES2051954T3 (es) 2-aminotiazoles substituidos.
GEP20032928B (en) Halo Derivatives of 9-Deoxo-9a-Aza-9a-Homerythromycin A, Method for its Production, Pharmaceutical Compositions Containing the Same and Their Use for Treatment or Prevention of Bacterial Infections
BG105247A (en) N-substituted azabicycloheptane derivatives, production and use thereof
HU9602228D0 (en) Condenzed azepine-derivatives of mercaptoacetylamide disulfides useful as inhibitors of enkephalinase, pharmaceutical compositions containing the same and process for producing them
ZA944317B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
DK514285D0 (da) 5-cyanopyridin-2-diazohydroxid, basiske salte og fremgangsmaader til deres fremstilling og anvendelse
NZ329716A (en) Sulfonamide substituted derivatives and medicaments thereof
HUT47897A (en) Process for producing salicilates and pharmaceutical compositions containing them
ES2060711T3 (es) 2-aminotiazoles substituidos.

Legal Events

Date Code Title Description
FC Refusal